References of "JERUSALEM, Guy"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailVISMODEGIB ET CARCINOMES BASOCELLULAIRES LOCALEMENT AVANCES
LEBAS, Eglantine ULg; RORIVE, Andrée ULg; EL HAYDERI, Lara ULg et al

in Revue Médicale de Liège (2015)

Basal cell carcinoma is the most frequent skin cancer. Even though metastases are exceptional, these cancers may be locally highly aggressive. The Hedgehog signaling pathway plays a significant role in ... [more ▼]

Basal cell carcinoma is the most frequent skin cancer. Even though metastases are exceptional, these cancers may be locally highly aggressive. The Hedgehog signaling pathway plays a significant role in the pathogenesis of basal cell carcinoma. Vismodegib is a selective inhibitor of this pathway and may be administered orally. Its main indication is locally advanced basal cell carcinoma, when other therapeutic options have failed or are contra-indicated. Vismodegib can also be used as prophylactic therapy in the Gorlin syndrome or basal cell nevomatosis. Its principal adverse effects are muscle spasms, alopecia and altered taste. They are frequent, but often moderate in intensity; they sometimes restrict continuation of treatment. Two clinical cases are presented, relating the efficacity and tolerance of this new therapeutic option. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailAgeism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads
Schroyen, Sarah ULg; Adam, Stéphane ULg; JERUSALEM, Guy ULg et al

in Clinical Interventions in Aging (2015), 10

Cancer is a major health problem that is widespread in elderly people. Paradoxically, older people suffering from cancer are often excluded from clinical trials and are undertreated when compared to ... [more ▼]

Cancer is a major health problem that is widespread in elderly people. Paradoxically, older people suffering from cancer are often excluded from clinical trials and are undertreated when compared to younger patients. One explanation for these observations is age stigma (ie, stereotypes linked to age, and thus ageism). These stigmas can result in deleterious consequences for elderly people’s mental and physical health in “normal” aging. What, then, is the impact in a pathological context, such as oncology? Moreover, health care professionals’ attitudes can be tainted with ageism, thus leading to undesirable consequences for patients. To counter these stigmas, we can apply some possible interventions emerging from research on normal aging and from social psychology, such as intergenerational contact, activation of positive stereotypes, self-affirmation, and so on; these tools can improve opinions of aging among the elderly people themselves, as well as health care professionals, thus affecting patients’ mental and physical health. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Peer Reviewed
See detailPersonnel soignant et âgisme: quelles conséquences cliniques ?
Schroyen, Sarah ULg; Missotten, Pierre ULg; JERUSALEM, Guy ULg et al

Conference (2014, December 16)

Introduction : Le cancer est un problème de santé majeur dont l’âge constitue un facteur de risque avéré1. Paradoxalement, les personnes âgées souffrant d’un cancer sont souvent exclues des essais ... [more ▼]

Introduction : Le cancer est un problème de santé majeur dont l’âge constitue un facteur de risque avéré1. Paradoxalement, les personnes âgées souffrant d’un cancer sont souvent exclues des essais cliniques et sous-traitées comparativement à des patients plus jeunes1. Un élément explicateur de ces constats est la stigmatisation liée à l’âge² (c.à.d. nos stéréotypes liés à l’âge, et donc l’âgisme). Méthodologie : Nous avons interrogé 76 infirmiers (-ères) travaillant en oncologie. A l’aide de fiches cli-niques, nous leur avons demandé s’ils encourageraient à des patients un traitement expérimental (40 vs 70 ans), une chimiothérapie ou une reconstruction mammaire (35, 55 ou 75 ans), tout paramètres cliniques étant équivalents par ailleurs. Résultats : L’encouragement d’un traitement expérimental est moins fréquente pour une personne de 70 ans comparativement à une personne de 40 ans (p<.001). De plus, le personnel soignant encourage moins fréquemment une chimiothérapie pour une personne de 75 ans comparativement aux per-sonnes de 55 et 35 ans (p<.001). Au niveau de la reconstruction mammaire, une différence est vi-sible dès 55 ans : la reconstruction mammaire est moins encouragée pour une personne de cet âge par rapport à une personne de 35 ans (p=.02) et encore moins encouragée pour une personne de 75 ans comparativement à une personne de 55 ans (p<.001). L’âge des infirmiers (M = 35.8) a une influence sur ces encouragement : plus ils sont âgés, plus ils encouragent le traitement chimiothérapeutique d’une per-sonne de 75 ans (p = .005) de même que le traitement expérimental pour une personne de 70 ans (p = .01). Conclusion : A l’instar d’autres études3, 4, nous confirmons que tant du point de vue esthétique que cura-tif, le personnel médical encourage moins fréquemment un traitement aux patients plus âgés compa-rativement aux plus jeunes. 1. Hurria, A., et al. (2012). J Natl Compr Canc Netw, 10, 162-209. 2. Penson, R. T., et al. (2004). The Oncologist, 9, 343-352. 3. Madan, A. K., et al. (2001). Acad Med, 76, 282-284. 4. Protière, C., et al. (2010). Crit Rev Oncol Hematol, 75, 138-150. [less ▲]

Detailed reference viewed: 26 (6 ULg)
Full Text
Peer Reviewed
See detailDouble stigmatization influence in oncogeriatry
Schroyen, Sarah ULg; Adam, Stéphane ULg; JERUSALEM, Guy ULg et al

in Psycho-oncology (2014, October 24)

Introduction Cancer is a major health problem widespread in elderly, which is inscribed in ageism context1. Negative influence of the vision that older people possess on aging on mental and physical ... [more ▼]

Introduction Cancer is a major health problem widespread in elderly, which is inscribed in ageism context1. Negative influence of the vision that older people possess on aging on mental and physical health2 is well established within “normal” aging. Consequently, we can ask ourselves what consequences age stigmas have in the realm of oncogeriatry. Moreover, cancerous patients face pathology-related stigmas because nowadays cancer still conveys a lot of negative representations. Method A group of 120 patients aged of 65 years old and more suffering from cancer (lung, breast or gynecological) will be followed during one year (0-3-6-12 months). Different instruments measuring quality of life, depression, symptoms, etc. are used as well as questions about their vision of aging and of cancer. Clinical parameters (weight, biologicals values, comorbidity…) are recorded too. Currently, we have 63 patients (31 breast cancer, 14 gynecological cancer and 18 lung cancer with distinction between smokers and non-smokers). Our analysis is only on the baseline at this moment, without any distinction between kinds of cancers. Results Double ANOVAs were used to analyze the data. A positive vision of aging is linked to a lower level of depression in comparison to a negative vision of aging (p = .04). Vision of pathology approach significance: less depression when vision is positive (p = .077). Concerning daily functioning (physical, emotional, social...), a positive vision of aging is related to a better functioning (p = .03) whereas vision of pathology has no effect. Eventually, a positive vision of aging and of cancer is related to a better quality of life (respectively p=.02, p=.002). Concerning clinical parameters, no results are observed. Conclusion These first results suggest that the vision patients have themselves of the age and of cancer is in relation with subjective mental and physical health. As we observe influence on vision of aging as well as pathology, we can talk about “double stigmatization”. Needless to say, more studies are needed to analyze the direction of these observation and longitudinal data analysis could bring some answers: is stigmatization provoke a less good mental and physical health or is it because I have health problem that I have a negative vision of aging and of my disease? 1. Penson, R. T., et al. (2004). The Oncologist, 9, 343-352. 2. Levy, B. (2009). Curr Dir Psychol Sci, 18, 332-336. [less ▲]

Detailed reference viewed: 41 (8 ULg)
Full Text
Peer Reviewed
See detailMulticenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians' general experiences and expectations.
Kenis, Cindy; Heeren, Pieter; Bron, Dominique et al

in Journal of geriatric oncology (2014), 5(4), 431-438

OBJECTIVES: The aim of this study is to identify treating physicians' general experiences and expectations regarding geriatric assessment (GA) in older patients with cancer. MATERIALS AND METHODS: A ... [more ▼]

OBJECTIVES: The aim of this study is to identify treating physicians' general experiences and expectations regarding geriatric assessment (GA) in older patients with cancer. MATERIALS AND METHODS: A survey was carried out in 9 Belgian hospitals, which participated in a national GA implementation project focusing on older patients with cancer. A newly developed questionnaire was completed by their treating physicians. Data collection comprised of reviewing hospital data, general respondent data, and treating physicians' general experiences and expectations regarding GA. Descriptive statistics were calculated. RESULTS: Eighty-two physicians from 9 hospitals participated. The GA team composition can vary substantially, with a nurse as core member. Ideally, all older patients with cancer in whom a treatment decision is necessary, should benefit from the GA. Nearly all GA domains are reported as very important. Availability of GA results can be improved. Treating physicians want geriatricians to coordinate geriatric recommendations related to the identified GA problems, and expect from trained healthcare workers (THCWs) to collect GA data, to report GA results, and to follow-up the implementation of geriatric recommendations. CONCLUSION: This study identifies relevant information for improving the implementation of GA in older patients with cancer in Belgium and reveals priorities for a THCW from the treating physician's point of view. To increase the effectiveness of GA, further efforts are needed to improve the implementation of geriatric recommendations. [less ▲]

Detailed reference viewed: 53 (3 ULg)
Full Text
Peer Reviewed
See detailEGFR activation and signaling in cancer cells are enhanced by the membrane-bound metalloprotease MT4-MMP.
Paye, Alexandra ULg; Truong, Alice ULg; Yip, Cassandre ULg et al

in Cancer research (2014)

MT4-MMP (MMP-17) is a GPI-anchored matrix metalloprotease expressed on the surface of cancer cells which promotes tumor growth and metastasis. In this report, we identify MT4-MMP as an important driver of ... [more ▼]

MT4-MMP (MMP-17) is a GPI-anchored matrix metalloprotease expressed on the surface of cancer cells which promotes tumor growth and metastasis. In this report, we identify MT4-MMP as an important driver of cancer cell proliferation through CDK4 activation and retinoblastoma protein (Rb) inactivation. We also determine a functional link between MT4-MMP and the growth factor receptor EGFR. Mechanistic experiments revealed direct association of MT4-MMP and its positive effects on EGFR phosphorylation in response to TGF- and EGF in cancer cells. Notably, the effects of MT4-MMP on proliferation and EGFR activation did not rely on metalloprotease activity. Clinically, MT4-MMP and EGFR expression were correlated in human triple negative breast cancer specimens. Altogether our results identify MT4-MMP as a positive modifier of EGFR outside-in signaling that acts to cooperatively drive cancer cell proliferation. [less ▲]

Detailed reference viewed: 21 (5 ULg)
Full Text
See detailEndocrine therapy resistance
JERUSALEM, Guy ULg

Conference (2014, September 19)

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailFertility and pregnancy after adjuvant therapy
JERUSALEM, Guy ULg

Conference (2014, September 19)

Detailed reference viewed: 7 (1 ULg)
See detailL'âgisme en oncogériatrie
Schroyen, Sarah ULg; Missotten, Pierre ULg; JERUSALEM, Guy ULg et al

Conference (2014, September 18)

Introduction (800 caractères): Le cancer est un problème de santé majeur dont l’âge constitue un facteur de risque avéré. Paradoxalement, les personnes âgées souffrant d’un cancer sont souvent sous ... [more ▼]

Introduction (800 caractères): Le cancer est un problème de santé majeur dont l’âge constitue un facteur de risque avéré. Paradoxalement, les personnes âgées souffrant d’un cancer sont souvent sous-traitées comparativement à des patients plus jeunes : à situation clinique équivalente, des futurs médecins recommandent moins fréquemment une reconstruction mammaire (Madan et al., 2004) et des médecins recommandent moins souvent une chimiothérapie (Protière et al., 2010) chez les personnes âgées par rapport aux jeunes. Un élément d’explication avancé par les auteurs est la stigmatisation liée à l’âge (c.à.d. nos stéréotypes liés à l’âge, et donc l’âgisme), bien qu’elle n’ait pas été analysée dans ces études. Dès lors, le lien entre la vision de l’âge et les recommandations cliniques constitue l’objectif de notre étude. Méthodologie (1500 caractères) : Nous avons interrogé 76 infirmiers (-ères) travaillant en oncologie et étant en contact régulier avec des patients âgés (67 femmes, 9 hommes, M âge = 33,88 ans). Il leur a été proposé de donner leur avis sur quatre fiches cliniques et de compléter deux questionnaires. La première fiche clinique concernait une nouvelle immunothérapie contre le cancer du poumon. A sa lecture, il était demandé aux infirmiers de noter, sur une échelle de 1 à 7, dans quelle mesure ils recommanderaient à leur patient (40 vs 70 ans) de suivre ce traitement expérimental. Les 3 autres fiches cliniques concernaient une patiente en bon état général atteinte d’un cancer du sein et ayant été traité par mastectomie. Les paramètres cliniques étaient strictement équivalents dans les 3 cas : seul l’âge de la patiente changeait (35, 55 ou 75 ans). Pour chaque fiche, les infirmiers devaient noter sur une échelle de 1 à 7 à quel point ils encourageraient le patient à suivre un traitement chimiothérapeutique et à demander une reconstruction mammaire Les infirmiers étaient également interrogés sur leur vision de l’âge de manière explicite via un questionnaire (FSA-R ; Boudjemad & Gana, 2009) et de manière implicite sur base des 5 premiers mots qui leur venaient à l’esprit lorsqu’ils pensaient à une personne âgée (informations récoltées au sein du questionnaire anamnestique global). Résultats (1500 caractères): Concernant le traitement expérimental, sa recommandation est moins fréquente pour une personne de 70 ans comparativement à une personne de 40 ans (p<.001). Cette moindre recommandation est associée à une tendance à citer plus de mots négatifs relatifs à la personne âgée (p =.09). Aucun résultat n’a été trouvé en lien avec la mesure explicite de l’âgisme. De plus, le personnel soignant recommande moins fréquemment une chimiothérapie pour une personne de 75 ans comparativement aux personnes de 55 et 35 ans (p<.001). Ce résultat ne semble pas influencer par la vision de l’âge du personnel soignant. Au niveau de la reconstruction mammaire, une différence est visible dès 55 ans : la reconstruction mammaire est moins recommandée pour une personne de cet âge par rapport à une personne de 35 ans (p=.02). Elle l’est encore moins pour une personne de 75 ans comparativement à une personne de 55 ans (p<.001). De plus, la différence de recommandation entre une personne de 75 et 35 ans semble être influencée par la vision de l’âge du personnel (mesurée par le test du FSA-R) : une vision plus négative est associée à un encouragement moins fréquent pour une personne de 75 ans comparativement à une personne de 35 ans (p = .01). Nous n’avons pas trouvé de lien avec la mesure implicite de l’âgisme. Conclusion (800 caractères): Nos données confirment que les recommandations cliniques telles qu’une reconstruction mammaire ou une chimiothérapie sont moins fréquente chez les personnes âgées que chez les jeunes. De plus, nos résultats montrent qu’une vision négative de l’âge est associée à une moindre propension à proposer une reconstruction mammaire. A l’inverse, la vision de l’âge ne semble pas influencer l’encouragement pour un traitement chimiothérapeutique : des attitudes âgistes sont observées même quand le personnel a une vision positive de l’âge. Ces résultats doivent cependant être confirmés par d’autres études notamment menées auprès d’autres professionnels en oncologie gériatrique. Lors de celles-ci, l’ajout d’autres mesures implicites de l’âgisme nous paraitrait intéressant. [less ▲]

Detailed reference viewed: 43 (6 ULg)
Full Text
Peer Reviewed
See detailNeoadjuvant chemotherapy in breast cancer induces miR-34a and miR-122 expression
FRERES, Pierre ULg; JOSSE, Claire ULg; Bovy, Nicolas ULg et al

in Journal of Cellular Physiology (2014)

Circulating microRNAs (miRNAs) have been extensively studied in cancer as biomarkers but little is known regarding the influence of anti-cancer drugs on their expression levels. In this article, we ... [more ▼]

Circulating microRNAs (miRNAs) have been extensively studied in cancer as biomarkers but little is known regarding the influence of anti-cancer drugs on their expression levels. In this article, we describe the modifications of circulating miRNAs profile after neoadjuvant chemotherapy (NAC) for breast cancer. The expression of 188 circulating miRNAs was assessed in the plasma of 25 patients before and after NAC by RT-qPCR. Two miRNAs, miR- 34a and miR-122, that were significantly increased after NAC, were measured in tumor tissue before and after chemotherapy in 7 patients with pathological partial response (pPR) to NAC. These 2 chemotherapy-induced miRNAs were further studied in the plasma of 22 patients with adjuvant chemotherapy (AC) as well as in 12 patients who did not receive any chemotherapy. Twenty-five plasma miRNAs were modified by NAC. Among these miRNAs, miR-34a and miR-122 were highly upregulated, notably in pPR patients with aggressive breast cancer. Furthermore, miR-34a level was elevated in the remaining tumor tissue after NAC treatment. Studying the kinetics of circulating miR-34a and miR-122 expression during NAC revealed that their levels were especially increased after anthracycline-based chemotherapy. Comparisons of the plasma miRNA profiles after NAC and AC suggested that chemotherapy-induced miRNAs originated from both tumoral and non-tumoral compartments. This study is the first to demonstrate that NAC specifically induces miRNA expression in plasma and tumor tissue, which might be involved in the anti-tumor effects of chemotherapy in breast cancer patients. [less ▲]

Detailed reference viewed: 51 (17 ULg)
Full Text
Peer Reviewed
See detailImpact de la double stigmatisation en oncogériatrie : Etat des lieux
Schroyen, Sarah ULg; Adam, Stéphane ULg; JERUSALEM, Guy ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(2), 131-8

Detailed reference viewed: 58 (24 ULg)
Full Text
See detailExtended adjuvant endocrine therapy. Who benefits ? For how long ?
JERUSALEM, Guy ULg

Conference (2014, April 24)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailNeoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Bonnefoi, H.; Jacot, W.; Saghatchian, M. et al

in Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (2014)

BACKGROUND: Neoadjuvant trials conducted using a double HER2-blockade with lapatinib and trastuzumab, combined with different paclitaxel-containing chemotherapy regimens, have shown high pathological ... [more ▼]

BACKGROUND: Neoadjuvant trials conducted using a double HER2-blockade with lapatinib and trastuzumab, combined with different paclitaxel-containing chemotherapy regimens, have shown high pathological complete response (pCR) rates, but at the cost of important toxicity. We hypothesised that this toxicity might be due to a specific interaction between paclitaxel and lapatinib. This trial assesses the toxicity and activity of the combination of docetaxel with lapatinib and trastuzumab. PATIENTS AND METHODS: Patients with stage IIA to IIIC HER2-positive breast cancer received six cycles of chemotherapy (three cycles of docetaxel followed by three cycles of fluorouracil, epirubicin, cyclophosphamide). They were randomised 1:1:1 to receive during the first three cycles either lapatinib (1000 mg orally daily), trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly), or trastuzumab+lapatinib at the same dose. The primary endpoint was pCR rate defined as ypT0/is. Secondary endpoints included safety and toxicity. pCR rate defined as ypT0/is ypN0 was assessed as an exploratory analysis. In June 2012, arm A was closed for futility based on the results from other studies. RESULTS: From October 2010 to January 2013, 128 patients were included in 14 centres. The percentage of the 122 evaluable patients with pCR in the breast, and pCR in the breast and nodes, was numerically highest in the lapatinib+trastuzumab group (60% and 56%, respectively), intermediate in the trastuzumab group (52% and 52%), and lowest in the lapatinib group (46% and 36%). Frequency (%) of the most common grade 3-4 toxicities in the lapatinib /trastuzumab/lapatinib+trastuzumab arms were: febrile neutropenia 23/15/10, diarrhea 9/2/18, infection (other) 9/4/8, and hepatic toxicity 0/2/8. CONCLUSIONS: This study demonstrates a numerically modest pCR rate increase with double anti-HER2 blockade plus chemotherapy, but suggests that the use of docetaxel rather than paclitaxel may not reduce toxicity. This study is registered with ClinicalTrials.gov, number NCT00450892. [less ▲]

Detailed reference viewed: 7 (0 ULg)